Clinical trials: Osteoporosis Postmenopausal
Postmenopausal Osteoporosis
Prevention of Osteoporosis in Breast Cancer Survivors
The purpose of this study is to test whether strength/weight training exercises enhance the effectiveness of calcium, vitamin D, and risedronate for the prevention and treatment of osteoporosis in postmenopausal breast cancer…
- Trial name
- NCT00567606
- Testing
- Strength/Weight Training & Drug/Supplement, Drug/Supplement only
- Where
- 4 sites in United States
- Volunteers
- 249 people
- Sponsor
- University of Nebraska
Postmenopausal Osteoporosis
Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD)
This was an open-label, single-center study to evaluate the usability of abaloparatide-sMTS by participants with low BMD.
- Trial name
- NCT04366726
- Testing
- abaloparatide-sMTS
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Radius Health, Inc.
Osteoporosis, Osteopenia or Osteoporosis
Assessment of Cortical Bone Mechanics Technology (CBMT) Fracture Discrimination Capability
Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue leading to bone fragility (i.e., weakness) and an increased risk for fracture.
- Conditions
- Osteoporosis, Osteopenia or Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Risk
- Trial name
- STRONGER (NCT05721898)
- Testing
- Cortical Bone Mechanics Technology
- Where
- 5 sites in United States
- Volunteers
- 394 people
- Sponsor
- Ohio University
Osteoporosis, Postmenopausal
Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
Denosumab of Intas is biosimilar denosumab candidate under development by Intas Pharmaceutical Limited (Biopharma Division). Denosumab of Intas is already approved by Indian drug licensing authority- Drug Controller General…
- Trial name
- NCT05419427
- Testing
- Denosumab, Denosumab-Ref
- Where
- India
- Volunteers
- 552 people
- Sponsor
- Lambda Therapeutic Research Ltd.
Osteoporosis, Postmenopausal
Efficacy and Safety of MW031 in PMO Subjects
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW031 in Chinese postmenopausal osteoporotic subjects with increased bone…
- Trial name
- NCT05215977
- Testing
- MW031
- Where
- China
- Volunteers
- 448 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Osteoporosis, Postmenopausal
ValoRization of Dairy Sidestreams to Fight Calcium dEficits iN Postmenopausal Women
The primary objective of this study is to investigate the effects of 12-months supplementation with calcium-enriched permeate, taken alone or in conjunction with inulin, on changes in markers of bone formation and resorption and…
- Trial name
- RENEW (NCT04836637)
- Testing
- Maltodextrin, Calcium-carbonate, Calcium-enriched permeate
- Where
- 2 sites in Denmark
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Osteoporotic Fractures, Osteoporosis, Postmenopausal
Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)
The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.
- Trial name
- ZEST II (NCT02589600)
- Testing
- Zoledronic acid, vitamin D, calcium
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- Susan L. Greenspan
Osteoporosis, Postmenopausal, Physical Activity
Efficacy and Safety of the Physical Activity Program in Women With Post-menopausal Osteoporosis
The study will be single blinded since professionals who will evaluate patients will not know to which exercise group patients have been assigned.
- Trial name
- ACTLIFE (NCT04179903)
- Testing
- Physical activity
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Istituto Ortopedico Rizzoli
Postmenopausal Osteoporosis
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
The purpose of this study is to examine, via iliac crest bone biopsies, the mechanism of combined teriparatide and denosumab on the bone of postmenopausal osteoporotic women after 3 months of treatment.
- Trial name
- NCT04026256
- Testing
- Teriparatide, Denosumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Postmenopausal, Osteoporosis
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
Osteoporosis remains a significant healthcare burden for the United States. Current FDA-approved osteoporosis treatments include teriparatide, abaloparatide, bisphosphonates, denosumab, and raloxifene.
- Trial name
- NCT03623633
- Testing
- denosumab, alendronate, raloxifene
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Postmenopausal
Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss
Postmenopausal osteoporosis is one of the important medical disorders affecting women after menopause. It is characterized by bone loss and reduced bone strength. In turn, this leads to increased risk of fracture.
- Trial name
- NCT04609189
- Testing
- Pearlium/EffectiCal, Calcium carbonate/vitamin D3
- Volunteers
- 97 people
- Sponsor
- University of Alberta
Osteoporosis, Postmenopausal
Psychological Determinants of the Therapeutic Observance of Osteoporotic Patients
Osteoporosis is a skeletal pathology characterized by decreased bone mass and deterioration of bone tissue. This pathology affects predominantly women, which is estimated that 40% of them will suffer an osteoporotic fracture.
- Trial name
- OSTEOPSY (NCT04029870)
- Where
- France
- Volunteers
- 152 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Postmenopausal Women With Osteoporosis
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
This study was conducted to assess if there were any clinically meaningful differences in pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety, or immunogenicity between GP2411 (proposed biosimilar denosumab) and…
- Trial name
- NCT03974100
- Testing
- GP2411, EU-Prolia (EU-authorized Prolia®)
- Where
- 42 sites in United States, Bulgaria and 4 more
- Volunteers
- 527 people
- Sponsor
- Sandoz
Hypovitaminosis D, Osteoporosis, Postmenopausal
Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis
Denosumab is a monoclonal antibody against RANKL ligand, which is used as an alternative treatment for osteoporosis in patients who have a poor response to first-line antiresorptive therapy.
- Conditions
- Hypovitaminosis D, Osteoporosis, Postmenopausal, Menopause
- Trial name
- NCT05372224
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 55 people
- Sponsor
- Hospital Regional 1o de Octubre
Postmenopausal Osteoporosis
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
A 12-month study to compare the efficacy and safety of abaloparatide-solid microstructured transdermal system (sMTS) with abaloparatide-subcutaneous (SC).
- Trial name
- NCT04064411
- Testing
- abaloparatide, abaloparatide solid microstructured transdermal system
- Where
- 97 sites in United States, Denmark and 3 more
- Volunteers
- 511 people
- Sponsor
- Radius Health, Inc.
Postmenopausal Osteoporosis
Prevention of Early Postmenopausal Bone Loss With Lactobacillus Reuteri
This study evaluates the effect of two different doses of Lactobacillus reuteri ATCC PTA 6475 (L.reuteri 6475) on bone loss in early postmenopausal women.
- Trial name
- ELBOWII (NCT04169789)
- Testing
- Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)
- Where
- Sweden
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Postmenopausal Osteoporosis, Diabetes Type 2
MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.
- Trial name
- NCT03472846
- Testing
- Prolia, 60 Mg/mL Subcutaneous Solution, Teriparatide
- Where
- Austria
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Postmenopausal Osteoporosis
Efficacy and Safety of Minodronate in Patients With Low Back Pain
This study will provide objective evidence for the efficiency and safety of minodronate in the treatment of postmenopausal osteoporosis with low back pain protocol.
- Trial name
- NCT05645289
- Testing
- Minodronate, Alendronate
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Peking University Third Hospital
Postmenopausal Osteoporosis
Quality of Life in Postmenopausal Women With Osteoporosis
The researchers will evaluate the effectiveness of a complex intervention composed of multiple actions targeting primary care healthcare workers and postmenopausal women with osteoporosis by means of a quasi-experimental design…
- Trial name
- NCT03970902
- Testing
- Integrated Osteoporosis Care, Care As Usual
- Where
- Belgium
- Volunteers
- 239 people
- Sponsor
- University Ghent
Hip Fractures, Osteoporosis, Postmenopausal
STRONG - Study of AGN1 LOEP for the Treatment of the Contralateral Femur After Fragility Fracture
To evaluate the procedure and safety profile of the AGN1 Femoral LOEP Kit. This pilot study will be used to evaluate AGN1 Femoral LOEP treatment in a contralateral proximal femur during hip fracture repair.
- Trial name
- NCT03268356
- Testing
- AGN1 Femoral Local Osteo-Enhancement Procedure Kit
- Where
- Hong Kong
- Volunteers
- 13 people
- Sponsor
- AgNovos Healthcare, LLC